About Kenneth Mace
Kenneth Mace is a chief financial officer at Alzheon.
Kenneth Mace first appears on SEC filings in 2016.
Experience
This experience comes from Kenneth Mace's profile and from SEC filings. For roles taken from filings, the years are when the filings name Kenneth Mace in the role, so the role may have started earlier or lasted longer.
Alzheon, Inc. Current
Chief Financial Officer
Vice President of Finance (2015 – 2017)
2015 – Present · Framingham, MA
Develops investigational medicines for people with Alzheimer’s and other neurodegenerative disorders.
FP
Flagship Pioneering
Vice President of Finance, New Ventures
2017 – 2021
RO
Roche
Vice Director - Group Planning
2012 – 2015
M2
mtm laboratories (Acquired by Roche in 2012)
Vice President, Finance and Operations
2006 – 2012
V2
ViaCell (Acquired by PerkinElmer in 2007)
Director Financial Planning & Analysis
2002 – 2006
C2
Cytyc Corporation (Acquired by Hologic in 2007)
Manager, Worldwide Financial Planning
2000 – 2002
BS
Boston Scientific
Regional Finance Manager - Latin America
1998 – 2000
TC
The Learning Company
Senior Accountant
1996 – 1997
Key Colleagues at Startups
The people Kenneth Mace works with at each company, as listed on that company's latest Form D.
Alzheon, Inc. · Form D, Sep 10, 2026
Christopher Dunn
Director
Neil Flanzraich
Executive Chairman of the Board of Directors
Diane Jorkasky, M.D.
Director
JD
John Hey, Ph.D.
Chief Scientific Officer
SD
Susan Abushakra, M.D.
Chief Medical Officer
MS
Muneer Satter
Director
Jordan Heller
Director
AM
Aidan Power, MRCPsych
Chief Development Officer
Gino Santini
Director
MD
Martin Tolar, M.D., Ph.D.
Founder, President & CEO, director
Adem Albayrak
Chief Data & AI Officer